Racial Disparities in Survival Outcomes of Diffuse Large B Cell Lymphoma: A Retrospective Cohort Study from 2000 to 2021

Introduction Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for 25-30% of all cases of NHL. DLBCL is an aggressive disease that can be cured in up to 50% of the patients who achieve complete remission following treatment with first-line therapy. In this study, we described the effect of race/ethnicity on survival outcomes among patients with DLBCL in the United States. Methods We extracted data on patients with a primary diagnosis of DLBCL from the Surveillance, Epidemiology and End Results (SEER) Registry. These patients had a primary diagnosis of DLBCL. We excluded patients with missing or unknown deaths, and Kaplan-Meier methods were used to estimate 5-year survival rates. Cox proportional hazards regression was used for multi-variable modelling of the survival database. The difference between the observed number of events between each group was compared using a log-rank statistical test. Results Our analysis revealed 99,415 patients with DLCBL. 82.8% (82,356) of patients were white, 7.2% (7244) of patients were black, 0.6% (602) were American Indian/Alaska Native, and 9.3% (9213) were Asian or Pacific Islanders. The one and five-year survival by race/ethnicity was White (75.9%, 64.0%), Black (72.6%, 60.6%), American Indian/Alaska Native (72.6%,61.1%) and Asian/Pacific Islander (76.5%,63.5%). Race/ethnicity proved to be a predictor of worse outcomes, with Asian/Pacific Islander HR 0.96 (95% CI; 0.92-0.99, p = <0.001), Black HR 1.01 (95% CI; 0.98-1.04, p = 0.629), American Indian/Alaska Native HR 1.06 (95% CI; 0.95-1.18, p = 0.294). There was no survival disparity by sex, male, HR 1.00 (0.98-1.02) p = 0.93. Conclusion Race plays a significant role in survival outcomes, with certain races associated with improved outcomes in patients with DLBCL. Asian/Pacific Islanders demonstrated a statistically significant improved survival outcome compared to whites. Of note, there was no disparity in survival outcomes by sex.

Authors

Institutions

Publication Details

Journal
Blood
Published
2024-11-05
DOI
https://doi.org/10.1182/blood-2024-212372
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Racial Disparities in Survival Outcomes of Diffuse Large B Cell Lymphoma: A Retrospective Cohort Study from 2000 to 2021

Ahmed Bashir Sukhera, Gloria Erazo, Oboseh John Ogedegbe, Tony E. Godfrey et al.
1 links
Blood
Lymphoma Diagnosis and Treatment
article

Racial Disparities in Survival Outcomes of Diffuse Large B Cell Lymphoma: A Retrospective Cohort Study from 2000 to 2021

Ahmed Bashir Sukhera, Gloria Erazo, Oboseh John Ogedegbe, Tony E. Godfrey, Serhan Ünlü, Asfand Yar Cheema, Jorge Rodriguez Vazquez
article en

Abstract

Introduction Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for 25-30% of all cases of NHL. DLBCL is an aggressive disease that can be cured in up to 50% of the patients who achieve complete remission following treatment with first-line therapy. In this study, we described the effect of race/ethnicity on survival outcomes among patients with DLBCL in the United States. Methods We extracted data on patients with a primary diagnosis of DLBCL from the Surveillance, Epidemiology and End Results (SEER) Registry. These patients had a primary diagnosis of DLBCL. We excluded patients with missing or unknown deaths, and Kaplan-Meier methods were used to estimate 5-year survival rates. Cox proportional hazards regression was used for multi-variable modelling of the survival database. The difference between the observed number of events between each group was compared using a log-rank statistical test. Results Our analysis revealed 99,415 patients with DLCBL. 82.8% (82,356) of patients were white, 7.2% (7244) of patients were black, 0.6% (602) were American Indian/Alaska Native, and 9.3% (9213) were Asian or Pacific Islanders. The one and five-year survival by race/ethnicity was White (75.9%, 64.0%), Black (72.6%, 60.6%), American Indian/Alaska Native (72.6%,61.1%) and Asian/Pacific Islander (76.5%,63.5%). Race/ethnicity proved to be a predictor of worse outcomes, with Asian/Pacific Islander HR 0.96 (95% CI; 0.92-0.99, p = <0.001), Black HR 1.01 (95% CI; 0.98-1.04, p = 0.629), American Indian/Alaska Native HR 1.06 (95% CI; 0.95-1.18, p = 0.294). There was no survival disparity by sex, male, HR 1.00 (0.98-1.02) p = 0.93. Conclusion Race plays a significant role in survival outcomes, with certain races associated with improved outcomes in patients with DLBCL. Asian/Pacific Islanders demonstrated a statistically significant improved survival outcome compared to whites. Of note, there was no disparity in survival outcomes by sex.

BloodVol. 144(Supplement 1)
The University of Texas of the Permian Basin (US), Texas Tech University (US), Trinity Health (US), Cleveland Clinic (US), Texas Tech University Health Sciences Center (US)
Good health and well-being
Openalex Percentile: Top 64%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.